Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057798 · ClinicalTrials.gov registry record · Phase 2
Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00057798 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 21 participants.
The verdict
NCT00057798, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Determination of genetic changes in patients with non-small cell lung cancer may help predict the outcome of treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them before surgery, may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase II trial to study genetic changes and the effectiveness of combining vinorelbine with gemcitabine before surgery in treating patients who have stage IB, stage II, or stage III non-small cell lung cancer.
Interventions
- GENETIC microarray analysis
- GENETIC cytogenetic analysis
- DRUG gemcitabine hydrochloride
- DRUG vinorelbine ditartrate
- GENETIC loss of heterozygosity analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2000-03 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057798
The ClinicalTrials.gov registry entry for NCT00057798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00057798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057798 about?
NCT00057798 is a clinical study titled "Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery". RATIONALE: Determination of genetic changes in patients with non-small cell lung cancer may help predict the outcome of treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them before surgery...
What is the current status of trial NCT00057798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2000-03. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00057798?
The interventions under investigation include: microarray analysis (GENETIC), cytogenetic analysis (GENETIC), gemcitabine hydrochloride (DRUG), vinorelbine ditartrate (DRUG), loss of heterozygosity analysis (GENETIC).
Who is sponsoring clinical trial NCT00057798?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.